Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06107868CT.gov Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uterine Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lunresertib (this asset) | University Health Network, Toronto | P1 | CC · 43 |
| GALFER | Sunnybrook Health Sciences Centre | P4 | BB |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Gynecologic Oncology Associates | P4 | BB |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Marcaine | University of California, Irvine | P3 | B |
| Sirexatamab | Leap Therapeutics, Inc. | P2 | B |
| Atezolizumab | Gradalis, Inc. | P2 | B |
| Durvalumab | Mary Crowley Medical Research Center | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Uterine Cancer cohort
Other indications for Lunresertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2 | CC · 46 |
| Ovarian Cancer | — | P1 | CC · 41 |
| Metastatic Malignant Neoplasm | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GALFERSunnybrook Health Sciences CentreBB
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Gynecologic Oncology AssociatesBB
- NivolumabNational Cancer Institute (NCI)B
- MarcaineUniversity of California, IrvineB
- SirexatamabLeap Therapeutics, Inc.B
Citation
Floatz Terminal. Lunresertib in Uterine Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lunresertib-uterine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →